Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution

  • Alnylam Pharmaceuticals, Inc. ALNY reported first-quarter FY23 revenues of $319.29 million, up 49.7% year over year, beating the consensus of $312.26 million.
  • Adjusted loss per share of $(1.06) beat the consensus of $(1.76) loss. 
  • Strength in Global Net Product sales (+48% Y/Y) to $276 million buoyed quarterly performance. In addition, the company saw solid commercial execution in Q1, driven by the ongoing launch of AMVUTTRA.
  • The company reported a Non-GAAP Net loss of $(131.89) million, narrower than the $(179.89) million loss in the year-ago period. 
  • Cash equivalents and marketable securities at quarter-end stood at $2.07 billion.
  • In Q1, the company delivered positive first-in-human results for an RNAi therapeutic in the CNS from an interim analysis of the Phase 1 study of ALN-APP in patients with early-onset Alzheimer's disease. "We believe this proof of concept is a significant catalyst for future potential growth for Alnylam," said CEO Yvonne Greenstreet.
  • Related: Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
  • Outlook: Alnylam reiterated its FY23 guidance, with Net Product Revenue growth in FY23 at 34%-44%.
  • Net revenues from collaborations and royalties is expected in the band of $100 million- $175 million. 
  • Price Action: ALNY shares are up 3.03% at $205.54 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEquitiesNewsGuidanceHealth CareMarketsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!